Full Text Journal Articles in
Journal J. Clin. Oncol.

Advertisement

Find full text journal articles






Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Anita Gul, Tyler F Stewart, Charlene M Mantia, Neil J Shah, Emily Stern Gatof, Ying Long, Kimberly D Allman, Moshe C Ornstein, Hans J Hammers, David F McDermott, Michael B Atkins, Michael Hurwitz, Brian I Rini,

Immune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903315]

Cited: 0 times

View full text PDF listing >>



Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.

David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede, Alexander V Louie, Cornelis Haasbeek, Liam Mulroy, Michael Lock, George B Rodrigues, Brian P Yaremko, Devin Schellenberg, Belal Ahmad, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Karen Moore, Suzanne Currie, Roel Schlijper, Glenn S Bauman, Joanna Laba, X Melody Qu, Andrew Warner, Suresh Senan,

PURPOSE:The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data that test this paradigm are lacking. METHODS:We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000818]

Cited: 0 times

View full text PDF listing >>



Advertisement

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

Steven F Powell, Kathryn A Gold, Mark M Gitau, Christopher J Sumey, Michele M Lohr, Steven C McGraw, Ryan K Nowak, Ashley W Jensen, Miran J Blanchard, Christopher D Fischer, Julie Bykowski, Christie A Ellison, Lora J Black, Paul A Thompson, Juan L Callejas-Valera, John H Lee, Ezra E W Cohen, William C Spanos,

PURPOSE:Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903156]

Cited: 0 times

View full text PDF listing >>



Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.

Effie W Petersdorf, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Katharina Fleischhauer, Ted Gooley, Mary Horowitz, J Alejandro Madrigal, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R Spellman, Jean Villard, Phil Stevenson, Mary Carrington, , ,

PURPOSE:The main aim of this study was to evaluate the significance of HLA-DPB1 expression in acute graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT) from HLA-A, -B, -C, -DRB1, -DQB1-matched and -mismatched unrelated donors. PATIENTS AND METHODS:Between January 1, 2017, and January 10, 2019, we assessed 19,136 patients who received ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000265]

Cited: 0 times

View full text PDF listing >>



Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study.

Jason A Beyea, Cindy Lau, Bonnie Cooke, Stephen Hall, Paul C Nathan, Sumit Gupta,

PURPOSE:Hearing loss is a significant late effect among childhood cancer survivors. Recent guidelines note insufficient evidence to quantify its natural history or risk associated with specific exposures. We examined the long-term incidence and predictors of hearing loss requiring hearing amplification devices (HADs) using population-based health care data. METHODS:In Ontario, Canada, ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903166]

Cited: 0 times

View full text PDF listing >>



Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

Young K Chae, Fangxin Hong, Christos Vaklavas, Heather H Cheng, Peter Hammerman, Edith P Mitchell, James A Zwiebel, S Percy Ivy, Robert J Gray, Shuli Li, Lisa M McShane, Larry V Rubinstein, David Patton, P Mickey Williams, Stanley R Hamilton, Aaron Mansfield, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty,

PURPOSE:NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring actionable aberration(s) in fibroblast growth factor receptor (FGFR) 1-3 were treated with AZD4547, an oral FGFR1-3 inhibitor. METHODS:Patients' tumors were screened by next-generation sequencing for predefined FGFR amplification, activating ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902630]

Cited: 0 times

View full text PDF listing >>



Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma.

Mark B Faries,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2001121]

Cited: 0 times

View full text PDF listing >>



ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Paolo Ghia, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Simkovic, Polina Kaplan, Iryna Kraychok, Arpad Illes, Javier de la Serna, Sean Dolan, Phillip Campbell, Gerardo Musuraca, Abraham Jacob, Eric Avery, Jae Hoon Lee, Wei Liang, Priti Patel, Cheng Quah, Wojciech Jurczak,

PURPOSE:Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS:Eligible patients, aged ≥ 18 years with R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903355]

Cited: 0 times

View full text PDF listing >>



Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.

Nancy U Lin, Virginia Borges, Carey Anders, Rashmi K Murthy, Elisavet Paplomata, Erika Hamilton, Sara Hurvitz, Sherene Loi, Alicia Okines, Vandana Abramson, Philippe L Bedard, Mafalda Oliveira, Volkmar Mueller, Amelia Zelnak, Michael P DiGiovanna, Thomas Bachelot, A Jo Chien, Ruth O'Regan, Andrew Wardley, Alison Conlin, David Cameron, Lisa Carey, Giuseppe Curigliano, Karen Gelmon, Sibylle Loibl, JoAl Mayor, Suzanne McGoldrick, Xuebei An, Eric P Winer,

PURPOSE:In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs. PATIENTS AND METHODS:Patients were randomly assigned 2:1 to ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000775]

Cited: 0 times

View full text PDF listing >>



Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

Charles M Rudin, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin Yang, Julien Mazieres, Francisco J Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P Kalemkerian, Yiwen Luo, Victoria Ebiana, M Catherine Pietanza, Hye Ryun Kim, ,

PURPOSE:Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC. METHODS:Eligible patients were randomly assigned 1:1 to pembrolizumab 200 mg once ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000793]

Cited: 0 times

View full text PDF listing >>



A Bitter Elixir: Palliative Chemotherapy During a Pandemic.

Amie E Jackson,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2001002]

Cited: 0 times

View full text PDF listing >>



Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients.

Thomas Lehrnbecher, Brian T Fisher, Bob Phillips, Melissa Beauchemin, Fabianne Carlesse, Elio Castagnola, Nathan Duong, L Lee Dupuis, Vicky Fioravantti, Andreas H Groll, Gabrielle M Haeusler, Emmanuel Roilides, Michelle Science, William J Steinbach, Wim Tissing, Adilia Warris, Priya Patel, Paula D Robinson, Lillian Sung,

PURPOSE:To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. METHODS:Recommendations were developed by an international multidisciplinary panel that included a patient advocate. We conducted a systematic review of systemic antifungal prophylaxis in children and adults with cancer and ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000158]

Cited: 0 times

View full text PDF listing >>



Sacramentality in Palliation.

Nathan A Dahl,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903182]

Cited: 0 times

View full text PDF listing >>



Smoldering Myeloma and the Art of War.

Sagar Lonial, Madhav V Dhodapkar, S Vincent Rajkumar,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000875]

Cited: 0 times

View full text PDF listing >>



The Road Less Traveled: Serving the Underserved.

Frederic Ivan L Ting,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1801925]

Cited: 0 times

View full text PDF listing >>



Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Mark Roschewski, Kieron Dunleavy, Jeremy S Abramson, Bayard L Powell, Brian K Link, Prapti Patel, Philip J Bierman, Deepa Jagadeesh, Ronald T Mitsuyasu, David Peace, Peter R Watson, Wahid T Hanna, Christopher Melani, Andrea N Lucas, Seth M Steinberg, Stefania Pittaluga, Elaine S Jaffe, Jonathan W Friedberg, Brad S Kahl, Richard F Little, Nancy L Bartlett, Michelle A Fanale, Ariela Noy, Wyndham H Wilson,

PURPOSE:Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma. METHODS:We conducted ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000303]

Cited: 0 times

View full text PDF listing >>



Trimodality Therapy for Muscle-Invasive Bladder Cancer: Concurrent Chemotherapy is Not Enough.

Eric Winquist, Christopher M Booth,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902959]

Cited: 0 times

View full text PDF listing >>



Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.

Martin Reck, Thomas Wehler, Francisco Orlandi, Naoyuki Nogami, Carlo Barone, Denis Moro-Sibilot, Mikhail Shtivelband, Jose Luis González Larriba, Jeffrey Rothenstein, Martin Früh, Wei Yu, Yu Deng, Shelley Coleman, Geetha Shankar, Hina Patel, Claudia Kelsch, Anthony Lee, Elisabeth Piault, Mark A Socinski,

PURPOSE:Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC). We present safety and patient-reported outcomes (PROs) to provide additional information on the relative impact of adding atezolizumab to chemotherapy with and without bevacizumab in nonsquamous NSCLC. METHODS:Patients ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1903158]

Cited: 0 times

View full text PDF listing >>



Postmastectomy and Regional Nodal Radiation for Breast Cancer.

Mylin A Torres, Kathleen C Horst, Gary M Freedman,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902908]

Cited: 0 times

View full text PDF listing >>



Integration of Breast Reconstruction and Postmastectomy Radiotherapy.

Dean A Shumway, Adeyiza O Momoh, Michael S Sabel, Reshma Jagsi,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902850]

Cited: 0 times

View full text PDF listing >>



De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.

E Shelley Hwang, Lawrence Solin,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902888]

Cited: 0 times

View full text PDF listing >>



Multidisciplinary Locoregional Management of Breast Cancer.

Benjamin D Smith, Elizabeth A Mittendorf, Bruce G Haffty,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000483]

Cited: 0 times

View full text PDF listing >>



Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery.

Elizabeth A Mittendorf, Jennifer R Bellon, Tari A King,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902891]

Cited: 0 times

View full text PDF listing >>



Oncoplastic Surgery in the Management of Breast Cancer.

Simona F Shaitelman, Jacqueline S Jeruss, Andrea L Pusic,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO1902795]

Cited: 0 times

View full text PDF listing >>



Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Mark Bustoros, Romanos Sklavenitis-Pistofidis, Jihye Park, Robert Redd, Benny Zhitomirsky, Andrew J Dunford, Karma Salem, Yu-Tzu Tai, Shankara Anand, Tarek H Mouhieddine, Selina J Chavda, Cody Boehner, Liudmila Elagina, Carl Jannes Neuse, Justin Cha, Mahshid Rahmat, Amaro Taylor-Weiner, Eliezer Van Allen, Shaji Kumar, Efstathis Kastritis, Ignaty Leshchiner, Elizabeth A Morgan, Jacob Laubach, Tineke Casneuf, Paul Richardson, Nikhil C Munshi, Kenneth C Anderson, Lorenzo Trippa, François Aguet, Chip Stewart, Meletios-Athanasios Dimopoulos, Kwee Yong, P Leif Bergsagel, Salomon Manier, Gad Getz, Irene M Ghobrial,

PURPOSE:Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2000437]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.879 s